Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if letrozole is effective at controlling
the growth or spread of estrogen and/or progesterone receptor positive uterine
leiomyosarcoma. This drug has been used in research studies for other cancers and is
currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone
levels in the body, it may be helpful to control tumors that express hormone receptors (
ER/PR).